In addition, the DNMT1 level was monitored before and after applying low-dose azacytidine to predict post-transplantation AML relapse, and the result hinted that a lower DNMT1 level before treatment might indicate a better response [108]. The gene discussed is DNMT1; the disease is acute myeloid leukemia.